샘플 요청 목록

 카트 문의
시장보고서
상품코드
1775063

세계의 십이지장궤양 치료 시장

Duodenal Ulcer Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 380 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 십이지장궤양 치료 시장은 2030년까지 50억 달러에 이를 전망

2024년에 45억 달러로 추정되는 십이지장궤양 치료 세계 시장은 2024-2030년의 분석 기간에 CAGR 2.0%로 성장하여 2030년에는 50억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 양성자 펌프 억제제는 CAGR 1.3%를 나타내고, 분석 기간 종료시에는 22억 달러에 이를 것으로 예측됩니다. H2 길항제 부문의 성장률은 분석 기간중 CAGR 2.8%로 추정됩니다.

미국 시장은 12억 달러로 추정, 중국은 CAGR 3.8%로 성장 예측

미국의 십이지장궤양 치료 시장은 2024년에 12억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년간 CAGR 3.8%로 2030년까지 9억 3,600만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 0.7%와 1.4%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 1.0%로 성장할 전망입니다.

세계의 십이지장궤양 치료 시장 - 주요 동향과 촉진요인 정리

십이지장궤양 치료는 왜 다면적인 치료로 진화하고 있는가?

십이지장궤양 치료는 기본적인 증상 완화에서 근본적인 원인 규명, 재발 억제, 합병증 예방을 목표로 하는 종합적인 다인자 접근법으로 크게 변화하고 있습니다. 과거에는 제산제와 식이요법이 중심이었으나, 현재 치료 전략에는 양성자 펌프 억제제(PPI), H2 수용체 길항제, 헬리코박터 파일로리 제균용 항생제, 점막 보호제, 병용요법 등 광범위한 의약품이 포함되어 있습니다. 헬리코박터 파일로리균이 원인균으로 발견되고, 산 억제와 함께 제균이라는 임상 패러다임이 근본적으로 바뀌면서 이러한 진화에 박차를 가했습니다. 또한, 항생제 내성 및 치료 실패에 대처하기 위해 2가지 항생제와 제산제를 조합한 3제 병용요법이나 4제 병용요법이 선호되고 있습니다. 일부 약제가 시판되어 접근성이 높아졌지만, 장기적인 치료와 순응도를 보장하기 위해 의사 주도의 치료 요법에 대한 관심이 다시금 높아지고 있습니다. 치료 범위는 약물 치료에 국한되지 않고 생활습관 상담, 식이요법, 경과 관찰을 위한 내시경 검사 등 환자 관리에 필수적인 요소로 자리 잡고 있습니다. 지연 방출 캡슐, 구강붕해정 등 약물 전달 시스템의 혁신도 환자의 순응도와 치료 성적을 향상시키고 있습니다. 이를 종합하면, 치료 상황은 개인 맞춤형 의료, 감염 관리, 증상 조절 전략의 교차점을 반영하고 있습니다.

기술이 진단 및 치료 모니터링의 임상 실습을 어떻게 재정의하고 있는가?

최근 십이지장궤양 치료에 사용되는 진단 및 모니터링 도구가 크게 개선되어 임상적 의사 결정 및 후속 치료에 변화를 가져왔습니다. 우레아 호흡 검사, 대변 항원 검사, 고급 혈청학적 검사 등 비침습적 진단 도구의 보급으로 십이지장궤양의 주요 원인인 헬리코박터 파일로리균 감염을 조기에 발견하는 비율이 크게 향상되었습니다. 보다 복잡한 사례나 재발이 반복되는 사례에서는 진단뿐만 아니라 치료 후 점막 치유를 모니터링하기 위해 고해상도 영상과 생검 기능을 갖춘 내시경 기술이 활용되고 있습니다. 전자 의료 기록과 AI를 통한 증상 추적 등 디지털 헬스 툴은 소화기내과 의사가 치료 요법을 보다 효과적으로 개별화할 수 있도록 돕고 있습니다. 또한, 약물유전체학(pharmacogenomics)은 개별 환자의 항생제 효과와 내성 패턴을 결정하는 중요한 요소로 부상하고 있으며, 이는 치료의 목표에 맞는 치료뿐만 아니라 지속적인 완화를 보장하는 데에도 기여하고 있습니다. 원격 의료 플랫폼의 부상도 특히 원격지에서 소화기 질환에 대한 접근성을 확대하여 궤양 증상의 적시 진단 및 관리를 용이하게 하고 있습니다. 또한, 복약 알림, 식단 모니터링, 증상 기록에 초점을 맞춘 모바일 건강 앱은 재발 예방에 필수적인 환자의 순응도를 돕습니다. 이러한 기술은 전 세계 의료 시스템에서 십이지장궤양 치료, 모니터링 및 관리 방법을 재구성하고 있습니다.

라이프스타일의 변화와 리스크 프로파일이 시장 변화에 미치는 영향은?

현대인의 라이프스타일의 변화는 십이지장궤양 치료 패턴의 변화의 원인이자 결과로 나타나고 있습니다. 스트레스, 불규칙한 식습관, 음주량 증가, 흡연, 비스테로이드성 항염증제(NSAIDs)의 과다 사용은 전 세계 십이지장궤양 발생에 크게 기여하고 있습니다. 이러한 역학적 변화로 인해 젊은 연령층, 여성, 기존과는 다른 환자군 등 보다 광범위한 계층이 영향을 받고 있습니다. 이에 따라 조기 개입 전략, 예방 검진, 전인적 치료 모델에 대한 수요가 증가하고 있습니다. 디지털 미디어와 헬스케어 아웃리치 프로그램에 힘입어 일반 대중의 소화기 건강에 대한 인식이 높아지면서 증상이 나타나면 진단을 받으려는 사람들이 증가하고 있으며, 이는 진단 및 치료제에 대한 시장 수요를 증가시키고 있습니다. 한편, 헬스케어 업계는 예방의학에 중점을 두고 있어 소화기 검진 및 내시경 시술에 대한 보험 적용이 확대되어 치료 장벽이 낮아지고 있습니다. 이와 함께 제약회사들은 궤양의 증상과 위험에 대한 인식을 높이기 위한 캠페인에 투자하고 있으며, 진단 및 치료제의 보급을 더욱 촉진하고 있습니다. 환자들의 기대치가 더 빠른 회복, 더 적은 부작용, 일상 생활에 대한 최소한의 장애로 진화함에 따라, 치료 솔루션은 내약성을 개선하고 재발률을 낮추면서 종합적인 치료를 제공하도록 재조정되고 있습니다.

십이지장궤양 치료 시장 수요 증가 요인은?

십이지장궤양 치료 시장의 성장은 기술 발전, 치료 프로토콜의 변화, 의료 인프라 개선, 환자 행동의 진화와 관련된 여러 요인에 의해 주도되고 있습니다. 특히 위생 상태가 아직 개선되지 않고 인식이 상대적으로 낮은 개발도상국에서 헬리코박터 파일로리균 감염의 전 세계 유병률 증가는 핵심 성장 요인 중 하나입니다. 이로 인해 의료 서비스 제공업체들은 보다 광범위한 검사와 표적화된 항생제 치료에 투자할 수밖에 없는 상황입니다. 또 다른 주요 원동력은 표준 항생제에 대한 내성 증가로, 새로운 약물 조합, 2차 치료 옵션, 새로운 항생제 계열과 같은 형태의 의약품 혁신을 촉진하고 있습니다. 실시간 PCR 검사 및 고해상도 내시경 검사와 같은 첨단 진단 도구가 더 널리 보급되고 통합됨에 따라 더 빠르고 정확한 진단이 가능해져 적시에 효과적인 치료를 받을 수 있는 환자 수가 증가하고 있습니다. 또한, 공중보건 노력, 보험 보급, 원격 의료 플랫폼은 신흥 시장의 의료 접근성을 확대하여 진단 및 치료율을 크게 향상시키고 있습니다. 비침습적 외래 기반 치료에 대한 환자들 수요는 편의성이 높은 제형과 치료 요법의 개발을 촉진하고 있습니다. 또한, 북미, 유럽, 아시아 일부 지역에서는 고령화와 비스테로이드성 항염증제(NSAID)의 사용 증가로 인해 궤양에 걸리기 쉬운 인구가 증가하면서 지속적인 수요를 견인하고 있습니다. 이러한 요인들은 예방적 헬스케어에 대한 트렌드와 위장 건강에 대한 지출 증가와 함께 세계 십이지장궤양 치료제 시장의 성장을 가속화하고 있습니다.

부문

치료제(양성자 펌프 억제제, H2 길항제, 항생제, 기타), 투여 경로(경구제, 비경구제), 유통 채널(병원 약국, 소매 약국, 기타)

조사 대상 기업 예

  • Abbott Laboratories
  • Acetelion Ltd
  • Actelion Pharmaceuticals Ltd.
  • Aralez Pharmaceuticals Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Boryung Pharmaceutical Co., Ltd.
  • Cadila Healthcare Ltd.(Zydus Cadila)
  • Daiichi Sankyo Company Limited
  • Dongkwang Pharmaceutical Co., Ltd.
  • GlaxoSmithKline plc
  • Jiangsu Carephar Pharmaceutical
  • Merck & Co., Inc.
  • Mylan Pharmaceuticals Inc.
  • Novartis AG
  • Pfizer Inc.
  • Ranbaxy Laboratories Limited
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.07.31

Global Duodenal Ulcer Treatment Market to Reach US$5.0 Billion by 2030

The global market for Duodenal Ulcer Treatment estimated at US$4.5 Billion in the year 2024, is expected to reach US$5.0 Billion by 2030, growing at a CAGR of 2.0% over the analysis period 2024-2030. Proton Pump Inhibitors, one of the segments analyzed in the report, is expected to record a 1.3% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the H2 Antagonists segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 3.8% CAGR

The Duodenal Ulcer Treatment market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$936.0 Million by the year 2030 trailing a CAGR of 3.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Duodenal Ulcer Treatment Market - Key Trends & Drivers Summarized

Why Is Duodenal Ulcer Treatment Evolving into a Multi-Faceted Therapeutic Landscape?

Duodenal ulcer treatment has transitioned significantly from basic symptom relief to a comprehensive, multifactorial approach aimed at targeting the root causes, reducing recurrence, and preventing complications. Historically managed primarily through antacids and dietary modifications, modern treatment strategies now include an extensive range of pharmaceuticals such as proton pump inhibitors (PPIs), H2-receptor antagonists, antibiotics for Helicobacter pylori eradication, mucosal protectants, and combination therapies. This evolution has been primarily fueled by the discovery of H. pylori as a causative agent, fundamentally shifting the clinical paradigm toward bacterial eradication alongside acid suppression. Additionally, there’s a rising preference for triple and quadruple therapies that combine two antibiotics with acid suppressants to address antibiotic resistance and treatment failures. Over-the-counter availability of certain medications has increased accessibility, but also prompted renewed focus on physician-led treatment regimens to ensure long-term healing and compliance. The treatment scope now increasingly extends beyond pharmacology, with lifestyle counseling, dietary guidance, and follow-up endoscopy becoming integral to patient care. Innovations in drug delivery systems such as delayed-release capsules and orally disintegrating tablets are also improving patient adherence and outcomes. Collectively, the treatment landscape reflects an intersection of personalized medicine, infection management, and symptom control strategies.

How Is Technology Redefining Clinical Practices in Diagnosis and Therapy Monitoring?

Recent years have witnessed a marked improvement in the diagnostic and monitoring tools employed in duodenal ulcer treatment, transforming clinical decision-making and follow-up care. The widespread adoption of non-invasive diagnostic tools, such as urea breath tests, stool antigen tests, and advanced serological assays, has significantly increased the early detection rate of H. pylori infections-one of the primary culprits behind duodenal ulcers. In more complex or recurring cases, endoscopic technologies equipped with high-resolution imaging and biopsy capabilities are being utilized to not only diagnose but also monitor mucosal healing post-treatment. Digital health tools, including electronic health records and AI-assisted symptom tracking, are now enabling gastroenterologists to personalize treatment regimens more effectively. Moreover, pharmacogenomics is emerging as a key factor in determining antibiotic efficacy and resistance patterns in individual patients, ensuring that therapies are not only targeted but also yield sustainable remission. The rise of telemedicine platforms has also expanded access to gastrointestinal consultations, especially in remote regions, facilitating timely diagnosis and management of ulcer symptoms. Additionally, mobile health apps focused on medication reminders, dietary monitoring, and symptom logging are supporting patient adherence, which is critical in preventing recurrence. These technological enablers are reshaping how duodenal ulcers are treated, monitored, and managed across healthcare systems globally.

What Role Do Changing Lifestyle Patterns and Risk Profiles Play in Market Shifts?

Modern lifestyle changes have emerged as both a cause and a consequence of shifting treatment patterns in the duodenal ulcer landscape. Stress, irregular eating habits, increasing alcohol consumption, smoking, and the overuse of nonsteroidal anti-inflammatory drugs (NSAIDs) are significantly contributing to the incidence of duodenal ulcers worldwide. This epidemiological shift is leading to a broader demographic being affected, including younger age groups, women, and non-traditional patient segments. Consequently, the demand for early intervention strategies, preventive screening, and holistic treatment models is rising. The growing public awareness around gastrointestinal health, fueled by digital media and healthcare outreach programs, is encouraging more individuals to seek diagnosis at the onset of symptoms, boosting market demand for both diagnostics and therapeutics. Meanwhile, the healthcare industry’s focus on preventive care is expanding insurance coverage for gastrointestinal consultations and endoscopic procedures, reducing barriers to treatment. In parallel, pharmaceutical companies are investing in campaigns that promote awareness about the symptoms and risks of ulcers, further propelling diagnostic and therapeutic uptake. As patient expectations evolve toward faster recovery, fewer side effects, and minimal disruption to daily routines, treatment solutions are being recalibrated to provide comprehensive care with improved tolerability and reduced recurrence rates.

What Is Fueling the Expanding Demand in the Duodenal Ulcer Treatment Market?

The growth in the duodenal ulcer treatment market is driven by several factors linked to technological progress, changing treatment protocols, healthcare infrastructure improvements, and evolving patient behavior. One of the core growth drivers is the rising prevalence of H. pylori infections globally, particularly in developing nations where sanitation conditions are still improving, and awareness remains relatively low. This is compelling healthcare providers to invest in more widespread testing and targeted antibiotic therapies. Another major driver is the increasing resistance to standard antibiotics, prompting pharmaceutical innovation in the form of novel drug combinations, second-line treatment options, and new antibiotic classes. The broader availability and integration of advanced diagnostic tools such as real-time PCR tests and high-definition endoscopy are allowing for earlier and more accurate diagnoses, thereby increasing the number of patients receiving timely and effective treatment. Furthermore, the expansion of healthcare access in emerging markets-driven by public health initiatives, insurance penetration, and telehealth platforms-is significantly enhancing diagnosis and treatment rates. Patient demand for non-invasive, outpatient-based therapies is encouraging the development of convenient formulations and treatment regimens. Additionally, aging populations in regions like North America, Europe, and parts of Asia are more prone to ulcers due to increased NSAID use, driving consistent demand. These factors, together with the trend toward preventive healthcare and rising expenditure on gastrointestinal wellness, are collectively accelerating the growth of the global duodenal ulcer treatment market.

SCOPE OF STUDY:

The report analyzes the Duodenal Ulcer Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Proton Pump Inhibitors, H2 Antagonists, Antibiotics, Others); Administration Route (Oral, Parenteral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Abbott Laboratories
  • Acetelion Ltd
  • Actelion Pharmaceuticals Ltd.
  • Aralez Pharmaceuticals Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Boryung Pharmaceutical Co., Ltd.
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Daiichi Sankyo Company Limited
  • Dongkwang Pharmaceutical Co., Ltd.
  • GlaxoSmithKline plc
  • Jiangsu Carephar Pharmaceutical
  • Merck & Co., Inc.
  • Mylan Pharmaceuticals Inc.
  • Novartis AG
  • Pfizer Inc.
  • Ranbaxy Laboratories Limited
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Duodenal Ulcer Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Gastrointestinal Disorders Throws the Spotlight on the Demand for Duodenal Ulcer Treatment
    • Increased Diagnosis Rates Due to Enhanced Endoscopic Capabilities Propel Growth in Early-Stage Ulcer Management
    • Widespread Use of NSAIDs and H. pylori Infections Expand the Addressable Market for Pharmacological Interventions
    • Innovation in Combination Drug Therapies and PPIs Strengthens the Business Case for Fast and Sustained Ulcer Relief
    • Growing Focus on H. pylori Eradication Drives Adoption of Antibiotic-Based Treatment Regimens
    • Improved Awareness of GI Health and Lifestyle Risk Factors Accelerates Patient Willingness to Seek Timely Treatment
    • Introduction of Novel Acid Suppressants and Mucosal Protective Agents Spurs Product Innovation and Market Differentiation
    • Telemedicine and Digital GI Consultations Create New Avenues for Diagnosis, Prescription, and Therapy Adherence
    • Increased Focus on Evidence-Based Treatment Guidelines Reinforces Market Confidence in Standardized Care Protocols
    • Integration of Probiotics and Gut Microbiota Modulators Opens Adjunctive Therapy Opportunities in Recurrent Ulcer Management
    • Expansion of OTC Gastrointestinal Product Lines Fuels Demand for Self-Managed Relief and Preventive Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Duodenal Ulcer Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Duodenal Ulcer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Duodenal Ulcer Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Proton Pump Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Proton Pump Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Proton Pump Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for H2 Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for H2 Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for H2 Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Duodenal Ulcer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Duodenal Ulcer Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Duodenal Ulcer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Duodenal Ulcer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Duodenal Ulcer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Duodenal Ulcer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Duodenal Ulcer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Duodenal Ulcer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제